ARTiDe: Autoantigen-specific adoptive regulatory T cell therapy against type 1 diabetes (ARTiDe)
POLTREG SPOLKA AKCYJNA
participó en un
HORIZON EUROPE:
HORIZON-HLTH-2022-DISEASE-06-two-stage
Type 1 diabetes (T1D) is an incurable disease, often starting in childhood, with a risk of devastating complications, premature mortality, a...
2023-04-27 - 2028-06-30 | Financiado
2023-04-27 - 2028-06-30 | Financiado
TREG: TREG innovative cell therapy targeting Diabetes Type 1
POLTREG SPOLKA AKCYJNA
tramitó un
H2020:
H2020-EIC-SMEInst-2018-2020
The main challenge of the project is to prepare and start Phase III of clinical development of TREG – a ground breaking Type 1 Diabetes (T1D...
2018-11-20 - 2023-10-31 | Financiado
2018-11-20 - 2023-10-31 | Financiado
TREGS4DM1: Commercialization of TREG cells sorting and proliferation in vitro for the production of vaccines fo...
POLTREG SPOLKA AKCYJNA
tramitó un
H2020:
H2020-SMEInst-2016-2017
The applicant aims at delivering economically sustainable and innovative cell therapy dedicated to the treatment of DM1 with the use of TREG...
2016-06-08 - 2016-12-31 | Financiado
2016-06-08 - 2016-12-31 | Financiado
* No se disponen de datos de la empresa actual.